Dr. Ram Yogendra

That the argument could be made as well, is this because of COVID or is this because of the vaccine?

That the argument could be made as well, is this because of COVID or is this because of the vaccine?

That's what we're doing. So what we're doing is we're saying if you had a vaccine injury, a documented vaccine injury, regardless of the time period, and you haven't had a COVID infection in the past year, you're enrolled in the study. When the paper comes out, you'll see there are different immune markers with the vaccine group compared to the COVID group.

That's what we're doing. So what we're doing is we're saying if you had a vaccine injury, a documented vaccine injury, regardless of the time period, and you haven't had a COVID infection in the past year, you're enrolled in the study. When the paper comes out, you'll see there are different immune markers with the vaccine group compared to the COVID group.

But right now, if you're trying to study this, it's going to be a mix because people that had vaccine injuries got COVID, and it's a big mishmash of things right now.

But right now, if you're trying to study this, it's going to be a mix because people that had vaccine injuries got COVID, and it's a big mishmash of things right now.

yeah so that's so that's the next thing you know i think the focus should be you know there's a lot of anything rightfully so discussions on the code uh the vaccines and the mandates and all of that that's going on but i think a lot of discussion needs to be made but we need to have more discussion with running clinical trials and get therapeutics you know i've been reading some some articles and and speculation that

yeah so that's so that's the next thing you know i think the focus should be you know there's a lot of anything rightfully so discussions on the code uh the vaccines and the mandates and all of that that's going on but i think a lot of discussion needs to be made but we need to have more discussion with running clinical trials and get therapeutics you know i've been reading some some articles and and speculation that

We're looking at about maybe 15 to 20 vaccine-injured patients in the United States, along with another 20 million or more that have long COVID. So if you take those numbers, you're looking at about 40 million, 50 million Americans that have COVID. long COVID or backs injured, you know, we're looking at about 15, 20% of the American population.

We're looking at about maybe 15 to 20 vaccine-injured patients in the United States, along with another 20 million or more that have long COVID. So if you take those numbers, you're looking at about 40 million, 50 million Americans that have COVID. long COVID or backs injured, you know, we're looking at about 15, 20% of the American population.

So, you know, and, and, you know, instead of looking maybe back and trying to point fingers, I, I'm more focused on looking forward and saying, how can we helping people helping, right?

So, you know, and, and, you know, instead of looking maybe back and trying to point fingers, I, I'm more focused on looking forward and saying, how can we helping people helping, right?

Yeah, you know what's really interesting? Some of these long COVID patients and even the vaccine-injured patients, what we're doing is we're actually finding also Lyme in them too. So we're finding reactivated herpes infections. The Yale study found that some of these vaccine-injured patients had low CD4 counts. There's some sort of immunosuppression taking place.

Yeah, you know what's really interesting? Some of these long COVID patients and even the vaccine-injured patients, what we're doing is we're actually finding also Lyme in them too. So we're finding reactivated herpes infections. The Yale study found that some of these vaccine-injured patients had low CD4 counts. There's some sort of immunosuppression taking place.

And with our long COVID patients, we saw CD8 counts that are low.

And with our long COVID patients, we saw CD8 counts that are low.

Yeah, I've seen that, you know, in fact, we have in our Vax paper, there is a potential, you know, a signal there with some of the immune markers, um, that might be that, that are sort of tumor checkpoints, um, that, that regulate the checkpoints and tumor, um, in angiogenesis. So. You know, I think there's a lot more to uncover with that spike protein and what was injected in people.

Yeah, I've seen that, you know, in fact, we have in our Vax paper, there is a potential, you know, a signal there with some of the immune markers, um, that might be that, that are sort of tumor checkpoints, um, that, that regulate the checkpoints and tumor, um, in angiogenesis. So. You know, I think there's a lot more to uncover with that spike protein and what was injected in people.

And we just need to have those uncomfortable conversations. The other thing, too, I just want to mention, Drew, that we can't study long COVID without acknowledging the vaccine, injured patients. Yeah. Congress has given $1.6 billion to the NIH, and no one knows where this money has gone. Stat News and Washington Post have been writing articles about this.

And we just need to have those uncomfortable conversations. The other thing, too, I just want to mention, Drew, that we can't study long COVID without acknowledging the vaccine, injured patients. Yeah. Congress has given $1.6 billion to the NIH, and no one knows where this money has gone. Stat News and Washington Post have been writing articles about this.